Retinitis Pigmentosa Clinical Trials

Find Retinitis Pigmentosa Clinical Trials Near You

Phase 2/3, Double-masked, Randomized, Sham-controlled, Single Dose Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)

Status: Recruiting
Location: See all (14) locations...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

The purpose of this clinical trial is to evaluate the effectiveness and safety of a single injection into the eye of an investigational gene therapy in participants with retinitis pigmentosa (RP).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults ≥18 years of age at the time of informed consent.

• Able and willing to provide written informed consent prior to any study-specific procedures, in accordance with ICH GCP and applicable regulations.

• Clinical diagnosis of RP, regardless of the underlying genetic mutation

• Baseline best corrected distance visual acuity (BCVA) in the study eye of LogMAR 1.0 and 2.7 inclusive (approximately 20/200 - 20/9000), measured monocularly at the ETF by certified, masked personnel using grating visual acuity with conversion to logMAR equivalents.

• Presence of retinal ganglion cells and/or retinal nerve fiber layer on SD-OCT testing at Screening confirmed by central image reading center.

• Adequate organ function and general good health

Locations
United States
Arizona
RayTx Clinical Site
NOT_YET_RECRUITING
Phoenix
California
RayTx Clinical Site
RECRUITING
Bakersfield
RayTx Clinical Site
RECRUITING
Beverly Hills
RayTx Clinical Site
NOT_YET_RECRUITING
Santa Barbara
Florida
RayTx Clinical Site
NOT_YET_RECRUITING
Deerfield Beach
Hawaii
RayTx Clinical Site
NOT_YET_RECRUITING
‘aiea
Illinois
RayTx Clinical Site
RECRUITING
Oak Park
Michigan
RayTx Clinical Site
NOT_YET_RECRUITING
Detroit
Minnesota
RayTx Clinical Site
NOT_YET_RECRUITING
Edina
North Carolina
RayTx Clinical Site
RECRUITING
Greensboro
New Jersey
RayTx Clinical Site
NOT_YET_RECRUITING
Bloomfield
Oregon
RayTx Clinical Site
RECRUITING
Portland
South Carolina
RayTx Clinical Site
RECRUITING
Mt. Pleasant
Texas
RayTx Clinical Site
NOT_YET_RECRUITING
San Antonio
Contact Information
Primary
Executive Medical Director
clinicaltrials@raytherapeutics.com
858-617-8610
Time Frame
Start Date: 2026-10
Estimated Completion Date: 2028-10
Participants
Target number of participants: 60
Treatments
Experimental: RTx-015 Lower Dose
RTx-015 Lower Dose
Experimental: RTx-015 Higher Dose
RTx-015 Higher Dose
Sham_comparator: Sham Control
Sham Control
Sponsors
Leads: Ray Therapeutics, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials